Sun Hong-Gang, Dong Xue-Jun, Lu Tao, Yang Ming-Feng, Wang Xing-Mu
Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6533-5. doi: 10.7314/apjcp.2013.14.11.6533.
The purpose of this study was to evaluate a new type of tumor biomarker, eukaryotic elongation factor 2 (eEF2), in serum for the early diagnosis, confirmative diagnosis as well as assessment of treatment of non-small cell lung cancer (NSCLC).
130 patients with NSCLC and 50 healthy individuals undergoing physical examination in our hospital provided the observation and healthy control groups. An enzyme linked immune sorbent assay (ELISA) method was applied to determine serum eEF2 levels. Serum neuron specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group were assessed with an automatic biochemical analyzer.
The median levels of eEF2 in the serum of NSCLC patients was found to be significantly higher than the healthy control group (p < 0.01) and it was markedly higher in stages III, IV than stages I, II (p < 0.05). eEF2 was higher with tumor size ≥ 2 cm than <2 cm (P< 0.01). Furthermore, two weeks after surgery patients showed a significant trend for eEF2 decrease (p < 0.05).
The eukaryotic elongation factor 2 (eEF2) has certain clinical values for early diagnosis, verification, and prognosis as well as classification of lung cancer patients.
本研究旨在评估一种新型肿瘤生物标志物——真核生物延伸因子2（eEF2）在血清中用于非小细胞肺癌（NSCLC）的早期诊断、确诊以及治疗评估的价值。
选取我院130例NSCLC患者作为观察组，50例健康体检者作为健康对照组。采用酶联免疫吸附测定（ELISA）法测定血清eEF2水平。观察组血清神经元特异性烯醇化酶（NSE）和鳞状细胞癌抗原（SCC）水平采用自动生化分析仪进行检测。
NSCLC患者血清中eEF2的中位数水平显著高于健康对照组（p < 0.01），且Ⅲ、Ⅳ期明显高于Ⅰ、Ⅱ期（p < 0.05）。肿瘤大小≥2 cm的患者eEF2水平高于<2 cm的患者（P< 0.01）。此外，术后两周患者的eEF2水平呈明显下降趋势（p < 0.05）。
真核生物延伸因子2（eEF2）在肺癌患者的早期诊断、确诊、预后评估及分型方面具有一定的临床价值。
